Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celcuity Inc CELC

Healthcare Biotechnology
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes... see more

Recent & Breaking News (NDAQ:CELC)

Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium

Accesswire December 10, 2021

Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium

Accesswire December 2, 2021

Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development

Accesswire November 29, 2021

Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial

Accesswire November 15, 2021

Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences

Accesswire November 9, 2021

Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Accesswire November 8, 2021

Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call

Accesswire October 29, 2021

Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases

Business Wire October 18, 2021

Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Accesswire August 9, 2021

Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference

Accesswire August 5, 2021

Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast

Accesswire August 2, 2021

Celcuity to Participate in the William Blair Biotech Focus Conference

Accesswire July 8, 2021

Celcuity Announces Pricing of Follow-on Offering

Accesswire June 28, 2021

Celcuity Announces Launch of Follow-on Offering

Accesswire June 28, 2021

Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations

Accesswire June 9, 2021

Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update

Accesswire May 10, 2021

Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast

Accesswire April 26, 2021

Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling

Accesswire April 12, 2021

Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update

Business Wire April 8, 2021

Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer

Business Wire April 8, 2021